FDA approves Mitapivat, the first oral treatment for thalassemia anemia, helping reduce transfusion needs and raise ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...